Lirilumab ELISA Kit (KPTX233)

货号	KPTX233
品牌	ProteoGenix
样本类型	Plasma, Serum
检测范围	0.31-5 μg/mL
保存溶液	The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
检测方法	Colorimetric
实验类型	Quantitative
回收率	80-120%
运输	2-8 ℃
规格	Lirilumab
别名	BMS-986015, IPH2102, CAS: 1000676-41-4
背景	Lirilumab (IPH2102/BMS-986015/BMS-986015-01) is a fully human monoclonal antibody (mAb) that is designed to block the interaction between KIR2DL-1,-2,-3 inhibitory receptors and their ligands. This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb. A phase 2 clinical trial for acute myeloid leukemia (AML) was terminated early ("failed") in 2017. It was registered for a trial for squamous cell carcinoma of the head and neck (SCCHN), but it may be abandoned. On 22 May 2018, a clinical trial for Bladder Cancer was started by PrECOG LLC.
Note	For Research Use Only.

概述